developments in targeted aml therapies: venetoclax, quizartinib & gilteritinib
Published 6 years ago • 250 plays • Length 3:15Download video MP4
Download video MP3
Similar videos
-
4:20
developments in therapies for aml - chemotherapy, targeted therapy and immunotherapy
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
1:33
developing targeted therapies to combine with venetoclax in acute myeloid leukemia (aml)
-
1:54
new developments in aml treatment
-
2:38
session highlights: transforming aml treatment and building on new approaches
-
20:27
acute myeloid leukemia (aml)
-
43:10
venetoclax plus gilteritinib for flt3-mutated relapsed/refractory acute myeloid leukemia
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
2:34
the evolution of the aml treatment paradigm
-
1:50
progress for gilteritinib and quizartinib for aml in the first-line setting
-
5:25
how the aml treatment landscape is changing with the introduction of novel targeted agents
-
3:58
targeted treatments for aml: the revolution
-
2:15
novel agents in trials for aml: quizartinib and gilteritinib
-
2:54
how novel agents & individualized treatment approaches are improving outcomes in patients with aml
-
3:40
how the aml treatment landscape has evolved with the use of novel combination therapies
-
3:08
venetoclax-idh inhibitor combination therapy for aml
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
4:38
novel combinations being explored in aml using an hma-venetoclax backbone
-
1:36
innovations in mds and aml treatment